The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer
BRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT CRC. We have used differential gene expre...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research
2018
|
| _version_ | 1797080221630857216 |
|---|---|
| author | Forsythe, N Refaat, A Javadi, A Khawaja, H Weir, J Emam, H Allen, W Burkamp, F Popovici, V Jithesh, P Isella, C LaBonte, M Mills, I Johnston, P Van Schaeybroeck, S |
| author_facet | Forsythe, N Refaat, A Javadi, A Khawaja, H Weir, J Emam, H Allen, W Burkamp, F Popovici, V Jithesh, P Isella, C LaBonte, M Mills, I Johnston, P Van Schaeybroeck, S |
| author_sort | Forsythe, N |
| collection | OXFORD |
| description | BRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT CRC. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n=31; validation set: n=26) CRC and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT CRC subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and unfolded protein response (UPR) pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT CRC cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT CRC. |
| first_indexed | 2024-03-07T00:57:02Z |
| format | Journal article |
| id | oxford-uuid:886f570f-1d5a-4e2a-8ca5-a4245bf4c541 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:57:02Z |
| publishDate | 2018 |
| publisher | American Association for Cancer Research |
| record_format | dspace |
| spelling | oxford-uuid:886f570f-1d5a-4e2a-8ca5-a4245bf4c5412022-03-26T22:17:14ZThe unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:886f570f-1d5a-4e2a-8ca5-a4245bf4c541EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research2018Forsythe, NRefaat, AJavadi, AKhawaja, HWeir, JEmam, HAllen, WBurkamp, FPopovici, VJithesh, PIsella, CLaBonte, MMills, IJohnston, PVan Schaeybroeck, SBRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT CRC. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n=31; validation set: n=26) CRC and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT CRC subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and unfolded protein response (UPR) pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT CRC cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT CRC. |
| spellingShingle | Forsythe, N Refaat, A Javadi, A Khawaja, H Weir, J Emam, H Allen, W Burkamp, F Popovici, V Jithesh, P Isella, C LaBonte, M Mills, I Johnston, P Van Schaeybroeck, S The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title_full | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title_fullStr | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title_full_unstemmed | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title_short | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| title_sort | unfolded protein response a novel therapeutic target for poor prognostic braf mutant colorectal cancer |
| work_keys_str_mv | AT forsythen theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT refaata theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT javadia theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT khawajah theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT weirj theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT emamh theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT allenw theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT burkampf theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT popoviciv theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT jitheshp theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT isellac theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT labontem theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT millsi theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT johnstonp theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT vanschaeybroecks theunfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT forsythen unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT refaata unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT javadia unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT khawajah unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT weirj unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT emamh unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT allenw unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT burkampf unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT popoviciv unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT jitheshp unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT isellac unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT labontem unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT millsi unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT johnstonp unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer AT vanschaeybroecks unfoldedproteinresponseanoveltherapeutictargetforpoorprognosticbrafmutantcolorectalcancer |